As a founding member of Psychedelic Institute Australia, he is a vocal advocate for evidence-based, accessible psychedelic care, and has contributed to leading journals including The Lancet and the Australian & New Zealand Journal of Psychiatry, where he promotes the integration of novel therapies into mainstream psychiatry.
He is the co-founder of Enosis Therapeutics, a company pioneering the fusion of immersive technology and psychedelic therapy. Enosis holds an Australian Innovation Patent for its groundbreaking clinical protocol that integrates Virtual Reality with psychedelic-assisted psychotherapy—an approach that has defined a new frontier in treatment, known as Spatial Therapeutics (STx).
Outside the clinical space, Dr. Prash is also the founder of Caleb & Brown, Australia’s largest personalised cryptocurrency brokerage, acquired in 2025 by Swyftx in the largest ever Crypto M&A transaction in ANZ. The firm was awarded Fintech Startup of the Year in 2018 for bridging traditional financial services with the emerging digital asset economy. His work in fintech reflects a broader mission to challenge outdated systems and design agile, tech-enabled infrastructure across industries.
Dr. Prash holds a Bachelor of Medicine and Bachelor of Surgery (Honours) from Monash University and a Master of Psychological Medicine from the University of Melbourne. In 2018, he was named Young Executive of the Year by the Australian Indian Executive Council for his visionary leadership across medicine and technology.
With a unique ability to straddle the clinical and commercial worlds, Dr. Prash is helping redefine the future of mental health-through innovation, ethical entrepreneurship, and a bold commitment to transformative change.